Healio Minute Podcast, Neurology Edition: Top Headlines - Week of April 18, 2022
Click Here to Manage Email Alerts
In this week’s edition, the FDA approval of an oral anticonvulsant; plus news you may have missed from the AAN and ACTRIMS meetings.
Read the full coverage here:
FDA approves oral anticonvulsant
New drug improved tic severity in children with Tourette syndrome
Vitamin D levels not associated with adverse outcomes in European MS patients
Zolpidem may be effective for prolonged disorders of consciousness
Amygdala overgrowth begins in first year of life in infants with ASD
References:
Gilbert DL, et al. ES1.002: Ecopipam in children and adolescents with Tourette syndrome: Results from a randomized, double-blind, placebo-controlled phase 2b study. Presented at: American Academy of Neurology annual meeting; April 2-7, 2022; Seattle.
Vasileiou E, et al. Vitamin D polygenic score and multiple sclerosis outcomes. Presented at: ACTRIMS Forum; Feb. 24-26; West Palm Beach, Florida.
Cassidy J, et al. Impact of zolpidem in the treatment of prolonged disorders of consciousness. Presented at: American Academy of Neurology annual meeting; April 2-7, 2022; Seattle.
Shen MD, et al. Am J Psychiatry. 2022;doi:10.1176/appi.ajp.21090896
Collapse
Read more about
Click Here to Manage Email Alerts
